Print Page  |  Close Window

News Release

HeartWare to Report 2010 Fourth Quarter and Year-End Financial Results

FRAMINGHAM, Mass. and SYDNEY, Feb. 15, 2011 /PRNewswire via COMTEX/ --

HeartWare International, Inc. (Nasdaq: HTWR, ASX: HIN) will release financial results for the fourth quarter and year ended December 31, 2010 prior to the open of the U.S. stock markets on Thursday, February 24, 2011.

A conference call with management is scheduled for 8:00 am U.S. Eastern Standard Time on Thursday, February 24, 2011 (being midnight Australian Eastern Daylight Time, between February 24 and February 25, 2011) to discuss the Company's financial results, highlights from the quarter and full year, and business outlook. The call may be accessed by dialing 1-877-941-2322 five minutes prior to the scheduled start time and referencing "HeartWare." For callers outside the U.S., please dial + 1-480-629-9715.

A live webcast of the call will also be available at the Company's website (www.heartware.com) by selecting "HeartWare Fourth Quarter Conference Call" under the section titled "Corporate Presentations" on the Home Page. A replay of the conference call will be available through the above weblink immediately following completion of the call.

A copy of the news release announcing results and related information will be available on the Company's web site, www.heartware.com.

About HeartWare International

HeartWare International develops and manufactures miniaturized implantable heart pumps, or ventricular assist devices, to treat Class IIIB / IV patients suffering from advanced heart failure. The HeartWare(R) Ventricular Assist System features the HVAD(R) pump, a small full-output circulatory support device (up to 10L/min flow) designed to be implanted next to the heart, avoiding the abdominal surgery generally required to implant competing devices. HeartWare has received CE Marking for the HeartWare System in the European Union. The device is currently the subject of United States clinical trials for two indications: bridge-to-transplant under a continued access protocol and destination therapy. For additional information, please visit www.heartware.com.

HeartWare International, Inc. is a member of the Russell 2000(R) and its securities are publicly traded on The NASDAQ Stock Market and the Australian Securities Exchange.

For further information:

Christopher Taylor

HeartWare International, Inc.

Email: ctaylor@heartwareinc.com

Phone: +1 508 739 0864

SOURCE HeartWare International, Inc.